SNORD28: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD28

NCBI ID: G9300

SNORD28

Other Name(s): Small nucleolar RNA, C/D box 28 | small nucleolar RNA, C/D box 28 | SNORD28A | U28 | RNU28

SNORD28: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help recruit chromatin-remodeling complexes to the site of gene transcription, allowing for the efficient translation of RNA into protein. One of the most well-known snRNAs is SNORD28, which is located within the C/D box of the 5' end of the gene.

SNORD28 is a small RNA molecule that consists of 19 nucleotides. It is expressed in almost all eukaryotic cells and plays an important role in the nucleus. Studies have shown that SNORD28 is expressed in different stages of the cell cycle, mainly expressed in the G1 phase and G2 phase, and the expression level decreases after the S phase and G2 phase. In addition, the expression of SNORD28 is also affected by many regulatory factors, including DNA-binding proteins, RNA-binding proteins and other proteins.

SNORD28 functions by binding to DNA to control gene expression. Studies have shown that SNORD28 can bind to many different DNA-binding partners, including histone A2F3, RNA-binding protein Sweep6, and DNA-binding protein DNMT1. These binding events can change the conformation of DNA, leading to the regulation of gene expression.

SNORD28 can also serve as a potential drug target. Studies have shown that SNORD28 can interact with many drugs, including anti-tumor drugs, anti-inflammatory drugs and immunomodulatory drugs. In addition, SNORD28 also interacts with many disease-related molecules, including neurodegenerative diseases, immunodeficiency diseases, and liver diseases. These interactions indicate that SNORD28 has great potential in drug development and disease treatment.

SNORD28 can also serve as a potential biomarker. Studies have shown that the expression level of SNORD28 can be detected by many biomarkers, including cell cycle, gene expression, proteomics, etc. These biomarkers can be used to monitor disease progression, treatment effectiveness and drug resistance, etc. In addition, the expression level of SNORD28 can also be used as an indicator to evaluate drug dosage and therapeutic effect.

As a non-coding RNA molecule, SNORD28 plays an important role in the nucleus and has great potential in drug development and disease treatment. The expression level of SNORD28 can be detected by many biomarkers and can be used to monitor disease progression, treatment effectiveness and drug resistance, etc. SNORD28 can also be used as a potential drug target, providing new ideas and strategies for drug development and disease treatment.

Protein Name: Small Nucleolar RNA, C/D Box 28

The "SNORD28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets